Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luxdegalutamide plus abiraterone versus enzalutamide plus abiraterone in high-volume metastatic hormone-sensitive prostate cancer
2024-520156-22-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Oct 2025
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, open-label trial of luxdegalutamide in prostate cancer (PCa) (2 arms), sponsored by Novartis. Primary endpoints: PSA90 rate, Safety and 1 more. Planned start Oct 2025; status: authorised.
02
Drugs
luxdegalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-520156-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520156-22-00.